WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer

WideTrial , one of TrialStat’s strategic partners has partnered with Oncotelic to bring the Expanded Access Platform to Cancer.

June 03, 2019 (ACCESSWIRE via COMTEX) — SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary of Mateon Therapeutics Inc., to provide OT-101 to patients who cannot take part in research trials of the investigational product. Under the partnership, WideTrial will sponsor and manage programs for treatment use of OT-101 in pancreatic cancer, advanced melanoma, colorectal cancer, and glioblastoma.

Continue Reading The Entire Announcement

You're Going to be Amazed By TrialStat

With TrialStat your studies will run smoothly, on-time and within budget.

Your Study Coordinators will enjoy the intuitive user interface and the speed in which they can enter their data. Schedule your personalized demo today to see first hand how TrialStat will transform your studies!

Close